Investigation the role of some biochemical variables in liver Cirrhosis
DOI:
https://doi.org/10.22317/imj.v6i4.1187Keywords:
Liver Cirrhosis, Nitric Oxide, Liver enzymesAbstract
Objectives: The current study is to assess nitric oxide levels as well as a few other biochemical parameters in individuals with hepatic Cirrhosis disease.
Methods: The study included 55 age-matched controls and 57 individuals with cirrhosis disease that were both clinically and biochemically identified. Adenosine deaminase (ADA), albumin, aspartate tansaminase (AST), alanine transaminase (ALT), -glutamyl transpeptidase (GGT), and alkaline phosphatase were measured as part of the biochemical analyses (ALP).
Results: The study group's serum nitric oxide (NO) levels were substantially (p 0.001) greater than those of the control group's. Additionally, the results showed that the activities of the enzymes ADA, GGT, ALP, AST, and ALT were significantly higher in liver cirrhotic patients than in the control group.
Conclusions: Nitric oxide concentration elevation may serve as a potential diagnostic indicator for liver cirrhosis.
References
-Liu, H., Gaskari, S.A. and Lee, S.S., 2006. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World journal of gastroenterology: WJG, 12(6), p.837.
-Deshmukh, A., More, U.K., Tilak, M.A., Sontakke, A.N. and Deshmukh, U.D., 2013. Role of Nitric Oxide in liver cirrhosis. Indian J of basic and applied medical res, 2(6), pp.546-550.
-Al-Hamoudi, W.K., 2010. Cardiovascular changes in cirrhosis: pathogenesis and clinical implications. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 16(3), p.145.
-Møller, S., Henriksen, J.H. and Bendtsen, F., 2014. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World Journal of Gastroenterology: WJG, 20(42), p.15499.
-Amirtharaj, G.J., Natarajan, S.K., Pulimood, A., Balasubramanian, K.A., Venkatraman, A. and Ramachandran, A., 2017. Role of oxygen free radicals, nitric oxide and mitochondria in mediating cardiac alterations during liver cirrhosis induced by thioacetamide. Cardiovascular toxicology, 17(2), pp.175-184.
-Guoyao, W.U. and Morris, S.M., 1998. Arginine metabolism: nitric oxide and beyond. Biochemical Journal, 336(1), pp.1-17.
-Moshage, H., Kok, B., Huizenga, J.R. and Jansen, P.L., 1995. Nitrite and nitrate determinations in plasma: a critical evaluation. Clinical chemistry, 41(6), pp.892-896.
-Antosova, M., Plevkova, J., Strapkova, A. and Buday, T., 2012. Nitric oxide—important messenger in human body. Open Journal of Molecular and Integrative Physiology, 2(03), p.98.
-Tsochatzis, E.A., Bosch, J. and Burroughs, A.K., 2014. Liver cirrhosis. The Lancet, 383(9930), pp.1749-1761.
-Bosch, J., Abraldes, J.G., Fernández, M. and García-Pagán, J.C., 2010. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. Journal of hepatology, 53(3), pp.558-567.
Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis. A role for nitric oxide. Lancet 1991;337:776-778.
Guarner C, Soriano G, Thomas A, Bulbena O, Novella MT, Balanzo J, Vilardell F, Mourelle M, Moncada S.Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology1993;18:1139-1143.
Genesca J, Gonzalez A, Sagura R, et al. Interleukin-6,nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am JGastroenterol 1999;94:169-177.
Albillos A, Rossi I, Cacha G, et al.Enhanced endothelium-dependent vasodilatation in patients with cirrhosis.Am J Physiol 268: G459-64, 1995.
Battista S, Bar F, Mengozzi G, Zanon E,Grosso M, Molino G. Hyperdynamiccirculation in patients with cirrhosis:direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol
:75-80, 1997.
Kanwar S, Kubes P, Tepperman BL Lee S. Nitric oxide synthase activity in portal hypertensive and cirrhotic rats. J Hepatol 1996;25:85-89.
Ohta M, Tanoue K, Tarnawski AS, et al. Overexpressed nitric oxide synthase in portal-hypertensive stomach of rat: a key to increased susceptibility to damage?Gastro-enterology 1997;112:1920-1930.
Heidebaugh J J, Brudevly M. Cirrhosis and chronic liver failure: Part I Diagnosis and evaluation. Am Fam Physician. 2006 Sep 1; 74(5):756-762.
Guarner C, Soriano G, Tomas A, et al.Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 18: 1139-43, 1993.
Pilette C, Moreau R, Sogni P, et al. Haemodynamic and hormonal responses to long-term inhibition of nitric oxide synthesis in rats with portal hypertension. Eur J Pharmacol 312:
-8, 1996.
-García-Pagán, J.C., Gracia-Sancho, J. and Bosch, J., 2012. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. Journal of hepatology, 57(2), pp.458-461.
-Koruk, M., Aksoy, H., Akçay, F. and Onuk, M.D., 2002. Antioxidant capacity and nitric oxide in patients with hepatic cirrhosis. Annals of Clinical & Laboratory Science, 32(3), pp.252-256.
-. Takahashi, M., Arai, Ohashi T., Wakayama, Y.,Satsuta, K. and Yunoki, H. (1984). Studies on the serum adenosine deaminase activity test in patients with hepatitis. Nippon Ika Diagaku Zasshi 51 (6), 768-771.
--. Wang, J.L., Yuan, S.Y. and Shao, J.F. (1986).Determination of serum adenosine deaminase :its diagnostic value in jaundice and liver fibrosis.Zhonghua Nei ke Za Zhi 25 (2), 79-81, 126.
-Kwo, P.Y., Cohen, S.M. and Lim, J.K., 2017. ACG clinical guideline: evaluation of abnormal liver chemistries. The American journal of gastroenterology, 112(1), p.18.
-Hyder, M.A., Hasan, M. and Mohieldein, A.H., 2013. Comparative levels of ALT, AST, ALP and GGT in liver associated diseases. European journal of experimental biology, 3(2), pp.280-284.
-Contreras-Zentella, M.L. and Hernández-Muñoz, R., 2016. Is liver enzyme release really associated with cell necrosis induced by oxidant stress?. Oxidative Medicine and Cellular Longevity, 2016.
-Bernardi, M., Ricci, C.S. and Zaccherini, G., 2014. Role of human albumin in the management of complications of liver cirrhosis. Journal of clinical and experimental hepatology, 4(4), pp.302-311.
--Kumar, P.A. and SuBramanian, K., 2016. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease. Journal of clinical and diagnostic research: JCDR, 10(3), p.BC09